Aurobindo Pharma Limited (NSE:AUROPHARMA)
1,807.20
-20.30 (-1.11%)
Nov 12, 2026, 3:29 PM IST
Aurobindo Pharma Revenue
Aurobindo Pharma had revenue of 102.63B INR in the quarter ending September 30, 2026, with 23.87% growth. This brings the company's total for the last twelve months to 369.13B, up 13.53% year-over-year. In the fiscal year ending March 31, 2026, Aurobindo Pharma had annual revenue of 336.53B with 6.08% growth. That makes Aurobindo Pharma the 3,138th largest company in the world by revenue and 88th in India.
Revenue (ttm)
369.13B
Revenue Growth
+13.53%
P/S Ratio
2.82
Revenue / Employee
12.64M
Employees
29,209
Market Cap
1.04T
Revenue by Geography
- USA 143.59B 42.7%
- Europe 106.88B 31.8%
- Rest of the World 52.78B 15.7%
- India 33.27B 9.9%
Fiscal year ended Mar 31, 2026 See the full Aurobindo Pharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 336.53B | 19.29B | 6.08% |
| Mar 31, 2025 | 317.24B | 27.22B | 9.39% |
| Mar 31, 2024 | 290.02B | 41.46B | 16.68% |
| Mar 31, 2023 | 248.55B | 14.00B | 5.97% |
| Mar 31, 2022 | 234.55B | -13.19B | -5.32% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zydus Lifesciences | 303.78B |
| Cipla | 279.89B |
| Glenmark Pharmaceuticals | 158.38B |
| Mankind Pharma | 153.79B |
| Alkem Laboratories | 150.81B |
| Divi's Laboratories | 121.91B |
| Ipca Laboratories | 104.70B |
| Emcure Pharmaceuticals | 102.34B |
Aurobindo Pharma News
- 2 days ago - Esperion Settles Patent Dispute With Aurobindo, Delays U.S. Generic Competition Until 2040 - Nasdaq
- 7 days ago - Aurobindo Pharma Transcript: Q2 26/27 - Transcripts
- 7 days ago - Aurobindo Pharma Quarterly report: Q2 2027 - Filings
- 7 days ago - Aurobindo Pharma Slides: Q2 2027 - Filings
- 8 days ago - India's Aurobindo Pharma's quarterly profit rises by a third on strong US demand - Reuters
- 8 days ago - Aurobindo Pharma reports 32.5% jump in Q2 net profit to ₹1,124 crore on record revenue from operations - The Times of India
- 5 weeks ago - Aurobindo arm Apitoria acquires A1 Biochem Labs LLC in $15.25M cash deal - The Times of India
- 1 month ago - Aurobindo arm Apitoria gets USFDA observation for Telangana API unit - The Times of India